Clinical efficacy andmetabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: A randomized study

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 636-641

  Romualdi, D ^a   De Cicco, S ^a   Busacca, M ^a   Gagliano, D ^a   Lanzone, A ^a,b   Guido, M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Androgens; Drospirenone; Ethinylestradiol; Metabolism; PCOS

Indexed keywords

ANDROSTANE DERIVATIVE; CHOLESTEROL; DROSPIRENONE; DRUG COMBINATION; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; BLOOD; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HIRSUTISM; HUMAN; HYPERANDROGENISM; PILOT STUDY; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANDROSTENES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; GLUCOSE CLAMP TECHNIQUE; HIRSUTISM; HUMANS; HYPERANDROGENISM; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; TRIGLYCERIDES;

MLCS; MLOWN;

EID: 84885618755     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346756     Document Type: Article

References (33)

1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005, 352: 1223-36.
2. Krysiak R, Okopien B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006, 58: 614-25.
3. Yildiz BO. Recent advances in the treatment of polycystic ovary syndrome. Expert Opin Investig Drugs 2004, 13: 1295-305.
4. Saha L, Kaur S, Saha PK. Pharmacotherapy of polycystic ovary syndrome- an update. Fundam Clin Pharmacol 2012, 26: 54-62.
5. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007, 24: CD005552.
6. Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005, 11: 277-91.
7. Soares GM, Vieira CS, de Paula Martins W, Dos Reis RM, de Sá MF, Ferriani RA. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract 2009, 63: 160-9.
8. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 2007, 22: 317-22.
9. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod 2011, 26: 191-201.
10. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002, 8: 231-41.
11. Silva Rdo C, Pardini DP, Kater CE. Polycystic ovary syndrome, metabolic syndrome, cardiovascular risk and the role of insulin sensitizing agents. Arq Bras Endocrinol Metabol 2006, 50: 281-90.
12. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006, 185: 227-39.
13. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011, 95: 1073-9.
14. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus > 20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2011, 1: CD 003989.
15. Stanczyk FZ. All progestins are not created equal. Steroids 2003, 68: 879-90.
16. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004, 89: 2817-23.
17. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2003, 19: 41-7.
18. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 2001, 76: 326-31.
19. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983, 57: 320-6.
20. Dietary Guidelines for Americans. Washington DC: US Dept of Agriculture, 1990.
21. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21: 1440-7.
22. Ciampelli M, Leoni F, Cucinelli F, et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005; 90: 1398-406.
23. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237: E214-23.
24. Endrikat J, Klipping C, Cronin M, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 2002, 65: 215-21.
25. Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol. Contraception 2006, 73: 336-43.
26. Endrikat J, Klipping C, Gerlinger C, et al. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. Contraception 2001, 64: 235-41.
27. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 2002, 47: 975-80.
28. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996, 54: 243-51.
29. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000, 62: 29-38.
30. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002, 69: 2-15.
31. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology 2000, 25: 513-8.
32. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med Suppl 1996, 738: 1-60.
33. Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992, 74: 64-70.